Overall (considering all types and stages of lung cancer), 16% of people with lung cancer survive for at least five years. Survival rates tend to be low when compared to the 65% five-year survival rate for colon cancer, 89% for breast cancer, and over 99% for prostate cancer.
People who have early stage (stage I) NSCLC and undergo lung surgery have a 60%-70% chance of surviving five years.
People with extensive nonoperable lung cancer have an average survival duration of nine months or less.
Those with limited SCLC who receive chemotherapy have a two-year survival rate of 20%-30% and a five-year survival rate of 10%-15%.
Less than 5% of people with extensive-stage SCLC (small cell cancers) are alive after two years, with a median survival range of eight to 13 months.
Showing posts with label prognosis. Show all posts
Showing posts with label prognosis. Show all posts
Thursday, 28 July 2011
Wednesday, 27 July 2011
bladder cancer prognosis
Prospects of human bladder cancer varies considerably, depending on the tumor stage at diagnosis.
Almost 90% of patients treated for superficial bladder cancer (Ta, T1, CIS) to survive for at least five years after treatment.
Only about 5% of people with metastatic bladder cancer survive at least two years after diagnosis.
Recurrent tumors more aggressive and show a poor outlook for long-term survival for patients with high stage bladder cancer or higher. Recurrent low-grade superficial bladder cancer is rarely fatal.
Almost 90% of patients treated for superficial bladder cancer (Ta, T1, CIS) to survive for at least five years after treatment.
Only about 5% of people with metastatic bladder cancer survive at least two years after diagnosis.
Recurrent tumors more aggressive and show a poor outlook for long-term survival for patients with high stage bladder cancer or higher. Recurrent low-grade superficial bladder cancer is rarely fatal.
Subscribe to:
Posts (Atom)